Today: 2 July 2026
Microsoft stock pops into earnings week as UBS trims target and Fed looms
25 January 2026
1 min read

Microsoft stock pops into earnings week as UBS trims target and Fed looms

New York, Jan 25, 2026, 09:47 EST — Market closed.

  • Microsoft shares climbed on Friday ahead of a crowded earnings week for mega-cap tech.
  • Analysts trimmed price targets but kept broadly positive views as Azure and AI spending stay in focus.
  • Attention turns to Wednesday’s Fed decision and Microsoft’s quarterly results.

Microsoft Corp shares rose 3.3% on Friday to close at $465.95, heading into the weekend on a firmer note after a choppy week for Wall Street. The stock traded between $450.60 and $471.10, with about 38 million shares changing hands.

The move matters now because investors will get Microsoft’s results on Jan. 28 in a heavy week for earnings from the biggest U.S. technology names, including Apple, Meta Platforms and Tesla. The Federal Reserve’s meeting lands in the same stretch, and strategists say rich valuations leave less room for a miss.

U.S. stocks finished the week modestly lower, with the Dow down 0.6% on Friday and the Nasdaq up 0.3% as traders digested Intel’s sharp slide on a downbeat forecast. Markets have swung this month on tariff headlines and shifting expectations for what comes next from policymakers.

Broker talk also played into Microsoft’s bounce. UBS analyst Karl Kierstead cut his price target on the stock to $600 but kept a buy rating, pointing to the ramp of Fairwater AI data centers as “key near-term catalysts for Microsoft Azure growth.” A price target is an analyst’s estimate of where the shares could trade in roughly a year. Nasdaq

Other firms have been trimming targets as well. Cantor Fitzgerald lowered its target to $590 from $639 while reiterating an overweight-equivalent rating, TipRanks reported; Morgan Stanley kept an overweight rating and a $650 target. The notes cited valuation “compression” — investors paying less for each dollar of earnings — across software. TipRanks

That debate is rolling straight into what some investors call the market’s “show-me” season for artificial intelligence, when big spending on data centers needs to start showing up as revenue. “You have to actually put up the revenue growth to justify the run-up in stocks,” said Julian McManus, a portfolio manager at Janus Henderson. Reuters

But the set-up cuts both ways. If Microsoft’s cloud growth slows, or if it signals heavier capital spending than investors expect, traders could treat Friday’s jump as a burst of positioning and sell the stock back down.

Microsoft said it will report fiscal second-quarter results after the market close on Wednesday, Jan. 28, and hold a conference call at 2:30 p.m. Pacific time. Traders will parse the outlook for Azure, corporate software demand and any comments on AI-related spending.

Earlier on Jan. 28, the Fed is scheduled to release its policy decision at 2:00 p.m. Eastern time, followed by a press conference at 2:30 p.m. The combination puts rate-sensitive mega-cap tech, including Microsoft, in focus for the next midweek test.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
Previous Story

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week

AAPL stock jumps nearly 3% as Morgan Stanley flags iPhone 17 strength ahead of Apple earnings
Next Story

AAPL stock jumps nearly 3% as Morgan Stanley flags iPhone 17 strength ahead of Apple earnings

Go toTop